Two Causes, One Solution

<section-header>



1L

140 mg/ml





GABBROVET® MULTI

Cryptosporidiosis is the most common cause of neonatal diarrhoea in calves under one month of age¹ and *E.Coli* is considered the 2nd most important pathogen affecting calves on U.K. farms².

Neonatal diarrhoea not only contributes to increased mortality, reduced growth rates ^{3,4}, delayed age at first calving and decreased milk production⁵ but contact with infected livestock has been found to be a source of human cryptosporidium infections in up to 38% of cases⁶.

Take control

of neonatal scour with GABBROVET® MULTI

Licensed to TREAT

Gabbrovet[®] Multi, containing paramomycin, is the first and only ready to use solution licensed in the U.K. to TREAT BOTH cryptosporidium and *E.Coli* diarrhoea in calves.

Fast and Effective

In a study of 334 calves with severe (≥ score 2) diarrhoea on inclusion, those receiving Gabbrovet® Multi showed a faster and more effective cure, by day 8, than those receiving halofuginone⁷.



Graph showing the reduction in diarrhoea for 334 calves treated with Gabbrovet® Multi vs. a halofuginone based product over an 8-day period⁷.

MULTI I40 mg/ml

*defined as the % of calves with a faecal score between 0 and 1, a general health status equal to 0 and hydration score equal to 0 for a minimum of two consecutive observations (day 7 and day 8 - 95% confidence interval >0).

Maintaining Growth

The mean daily body weight gain (MDBWG) of the calves treated with Gabbrovet Multi[®] was just over 0.04kg per day higher than those treated with halfuginone based products (p = 0.0086), leading to an **overall body weight advantage of 850g per calf after 3 weeks**⁷.

Two Causes, One Solution

Trusted Safety Profile



Gabbrovet Multi^{*} is **well tolerated** up to **3 times** the recommended dose and for an extended treatment period of **15 days**[®]



The therapeutic interval for halofuginone products is narrow and **signs of intoxication** may already appear at **2 times** the recommended dose⁹

GABBROVET® MULTI, a combined solution for the treatment of two major causes of scour in newborn calves

Dosage and Duration of Treatment

The dosage of Gabbrovet[®] Multi has been carefully researched and titrated to find the optimum protocol for the **treatment** of calves with cryptosporidiosis. Following this dosing regime will promote improved recovery times and help support responsible use of antibiotic protocols on-farm.

		Escherichia coli	Cryptosporidium parvum
S.	Dosage	1.25 - 2.5 ml /10 kg BW/day	7.5ml /10 kg BW/day
	Duration of treatment	3-5 days	5 days
Solver and the second s	Mode of administration	Drench, mixed in milk or milk replacer	Drench, mixed in milk or milk replacer
Ø	Withdrawal time for meat and offal	20 days	110 days

As part of a comprehensive scour reduction programme, management changes should also be discussed, including:



An enhanced colostrum strategy



Hygiene and disinfection in calf areas to reduce infection pressure



Prevention of overcrowding in calf rearing pens



Elimination of stress where possible

	\frown	
(ഫ്	
	I≡žI	
\backslash		
	\sim \sim	

Accurate record keeping and planning

GABBROVET® MULTI – A Convenient Solution for Scour in Calves

- Administration in milk, milk replacer or as a drench
- Ready-to-use solution
- 🗹 Available with a dosing cap
- 🗹 Easy to store in cardboard box
- Convenient range of presentations (250 mL, 500 mL, 1 L)
- 🗹 Can be used up to 6 months after opening

Ceva's Comprehensive Treatment Range Supporting Scouring Calves



Alongside Gabbrovet[®] Multi, Ceva Animal Health has a wide range of products to support the management of calves with scour:



Meloxidyl®

containing meloxicam, Meloxidyl reduces the inflammation associated with scour and has antiendotoxic properties" - encouraging calves to feel more comfortable, continue feeding and maintain growth¹².



Rehydion®

an oral rehydration therapy gel that provides sufficient essential electrolytes to correct acidosis whilst still allowing continued milk feeding (when given at the recommended levels) as it does not disturb milk clot formation or delay abomasal emptying¹³.



contains montmorillonite, which maintains intestinal function by coating and protecting enterocytes and absorbing the toxins produced by pathogenic bacteria¹⁴. Prebiotics (fructo-oligosaccharides) promote the growth of beneficial gut microflora; may prevent the adhesion of *Enterobacteriaceae* (e.g. *E-Coli*) and stimulate the production of short chain fatty acids^{15,16}.

References: 1. Thomson, S., Hamilton, C.A., Hope, J.C. *et al.* Bovine cryptosporidiosis: impact, host-parasite interaction and control strategies. Vet Res 48, 42 (2017). https:// doi.org/10.1186/s13567-017-0447-0 • 2. FMR Global Health / survey conducted in FR, GER, UK, BE, DK, PL and SP in March 2022 • 3. Pardon, B., Hostens, M., Duchateau, L. *et al.* Impact of respiratory disease, diarrhoea, otitis and arthritis on mortality and carcass traits in white veal calves. BMC Vet Res 9, 79 (2013). https://doi.org/10.1186/1746-6148-9-79 • 4. Windeyer MC, Leslie KE, Godden SM, Hodgins DC, Lissemore KD, LeBlanc SJ. Factors associated with morbidity, mortality, and growth of dairy heifer calves up to 3 months of age. Prev Vet Med. 2014 Feb 113(2):231-40. doi: 10.1016/j.prevetmed.2013.10.019) • 5. Svensson C, Hultgren J. Associations between housing, management, and morbidity during rearing and subsequent first-lactation milk production of dairy cows in southwest Sweden. J Dairy Sci. 2008 Apr;91(4):1510-8. doi: 10.3168/jds.2007-0235.
• 6. Chalmers RM, Robinson G, Elwin K, Elson R. Analysisof the Cryptosporidium spp. and gp60 subtypes linked to human outbreaks of cryptosporidiosis in England and Wales, 2009 to 2017. Parasit Vectors. 2019 Mar 12;12(1):95. doi: 10.1166/s13071-019-3354-6.
• 7. Daminen Achard, Béatrice Besche-Barbazanges, Gaëlle Pagny, Jean-François Collin, Dejan Cvejić. Efficacy of an oral solution of paromonycin for the treatment of newborn dairy calves with cryptosporidiosis - Results from a comparative European multicentric field study, Presented at the 31st World Buiatrics Congress 2022. Study report CLT/C651/1732 & ST-CLT/C651/1731, Ceva Santé Animale • 8. Gabbrovet Multi 140 mg/ml Solution for Use in Drinking Water/Milk for Pre-ruminant Cattle and Pigs Summary of Product Characteristics: https://www.rmd.defra.gov.uk • 10. Foster, D. M., and G. W. Smith. 2009. Pathophysiology of diarrhea in calves. 92:296-312. • 14. Depuis (1996), Es argiles en therapeutory drug therapy for

Gabbrovet* Multi 140 mg/ml Solution for Use in Drinking Water/Milk for Pre-ruminant Cattle and Pigs contains 140 mg paromomycin (as sulfate). Indications: Pre-ruminant cattle: Colibacillosis: Treatment of gastro-intestinal infections caused by Escherichia coli susceptible to paromomycin. Cryptosporidiosis: Treatment of infections caused by Escherichia coli susceptible to paromomycin. Cryptosporidiosis: Treatment of infections caused by Escherichia coli susceptible to paromomycin. Cryptosporidiosis: Treatment of infections caused by Escherichia coli susceptible to paromomycin. Contraindications: Do not use in animals with known hypersensitivity to paromomycin, other aminoglycosides or any of the excipients. Do not use in cases with impaired function of the kidneys or liver. Do not use in numinating animals. Do not use in turkeys due to the risk of selection for antimicrobial resistance in intestinal bacteria. Adverse reactions: In rare ocasions soft facess reactions) - common (more than 1 but less than 10 animals treated) - uncommon (more than 1 but less than 10 animals in 1000 animals treated) - uncommon (more than 1 but less than 10 animals in 1000 animals treated) - uncommon (more than 1 but less than 10 animals in 1000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but less than 10 animals in 10,000 animals treated) - uncommon (more than 1 but

bar on bin year salade by the Wrady in trace of instants of the protect of the animatic relation of the relation of the animatic relation of the a

Meloxidyl* 20 mg/ml solution for injection for cattle, pigs and horses contains 20 mg/ml meloxicam. Legal category: UK [POM-V] Further information is available from the SPC, pack insert or datasheet at www.noahcompendium.co.uk or upon request.

Prescription decisions are for the person issuing the prescription alone. Use medicines responsibly (www.noah.co.uk/responsible)

Ceva Animal Health Ltd,

Explorer House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, Buckinghamshire, HP10 0HH 01628 334056 www.ceva.co.uk

